C4 Therapeutics Stock Forecast

Stock Price Forecast

According to 7 analysts polled by S&P Global, C4 Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $13.33. The average 1-year stock price forecast is 223.54% higher than the current stock price, while the lowest is $7.00 (+69.90%) and the highest is $30 (+628.16%).

Price Target: $13.33 (+223.54%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$7.00	$13.33	$11	$30
Change	+69.90%	+223.54%	+166.99%	+628.16%

Analyst Ratings

The average analyst rating for C4 Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	7	7	7	7	7	6
Buy	1	1	1	1	1	1
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	8	8	8	8	8	7

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Etzer Darout Barclays	Barclays	Buy Maintains $7	Buy	Maintains	$7	+69.90%	Jun 12, 2026
Derek Archila Wells Fargo	Wells Fargo	Buy Reiterates $10	Buy	Reiterates	$10	+142.72%	May 13, 2026
Tyler Van Buren TD Cowen	TD Cowen	Buy Maintains n/a	Buy	Maintains	n/a	n/a	May 12, 2026
Akash Tewari Jefferies	Jefferies	Buy Maintains $14	Buy	Maintains	$14	+239.81%	Apr 30, 2026
Bradley Canino Guggenheim	Guggenheim	Buy Reiterates $7	Buy	Reiterates	$7	+69.90%	Feb 27, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

18.93M

from 35.95M

-47.35%

from 35.95M

Revenue Next Year

19.14M

from 18.93M

1.14%

from 18.93M

EPS This Year

-0.96

from -1.14

EPS Next Year

-1.04

from -0.96

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	45.79M	31.10M	20.76M	35.58M	35.95M	18.93M
Revenue Growth	37.93%	-32.08%	-33.25%	71.44%	1.02%	-47.35%
Gross Profit	-48.88M	-86.75M	-96.95M	23.05M	26.97M	18.93M
Gross Margin	-106.76%	-278.96%	-467.09%	64.76%	75.03%	100.00%
Operating Income	-82.13M	-129.53M	-139.03M	-117.18M	-104.49M	-137.88M
Net Income	-83.89M	-128.18M	-132.49M	-105.32M	-104.99M	-119.18M
EPS	-	-	-	-	-1.14	-0.96
Free Cash Flow	-30.22M	-62.78M	-66.06M	-35.43M	-54.30M	-108.00M
No. Analysts	-	-	-	-	-	4

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	29.7M
Avg	18.9M
Low	6.0M

Revenue Growth

Revenue Growth	2026	2027	2028
High	-17.4%
Avg	-47.4%
Low	-83.3%

EPS Forecast

EPS	2026	2027	2028
High	-0.83
Avg	-0.96
Low	-1.06

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-